The Readout Loud cover image

212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy

The Readout Loud

00:00

What's the Biggest Loser Coming Out of Ascoare?

Gilead sciences has been in the news at cancer conferences for years. The company is trying to become a player in developing cancer treatment that might have practice changing data like you just described. Adam: Biggest loser coming out of asco from a corporate perspective was gilead Sciences. He says there's even a discussion, i think, that tordelvi could encroach into metastatic triple negative breast cancer.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app